HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >

Clinical significance of minimal residual disease in adult acute lymphoblastic leukemia

Files in This Item:
IJH92-3_481-489.pdf868.74 kBPDFView/Open
Please use this identifier to cite or link to this item:

Title: Clinical significance of minimal residual disease in adult acute lymphoblastic leukemia
Authors: Kikuchi, Misato Browse this author
Tanaka, Junji Browse this author →KAKEN DB
Kondo, Takeshi Browse this author
Hashino, Satoshi Browse this author
Kasai, Masaharu Browse this author
Kurosawa, Mitsutoshi Browse this author
Iwasaki, Hiroshi Browse this author
Morioka, Masanobu Browse this author
Kawamura, Tsugumichi Browse this author
Masauzi, Nobuo Browse this author
Fukuhara, Takashi Browse this author
Kakinoki, Yasutaka Browse this author
Kobayashi, Hajime Browse this author
Noto, Satoshi Browse this author
Asaka, Masahiro Browse this author
Imamura, Masahiro Browse this author
Keywords: MRD
Adult ALL
Allogeneic transplantation
Polymerase chain reaction
Flow cytometry
Issue Date: Oct-2010
Publisher: Springer Japan
Journal Title: International Journal of Hematology
Volume: 92
Issue: 3
Start Page: 481
End Page: 489
Publisher DOI: 10.1007/s12185-010-0670-1
PMID: 20830615
Abstract: Monitoring minimal residual disease (MRD) in patients with acute lymphoblastic leukemia (ALL) is a useful way for assessing treatment response and relapse. We studied the value of MRD and showed a correlation with relapse for 34 adult patients with ALL. MRD was evaluated by real-time quantitative polymerase chain reaction (RQ-PCR) with probes derived from fusion chimeric genes (BCR/ABL) (n = 12) or PCR-based detection of clonal immunoglobulin and T-cell receptor gene rearrangements (n = 16), or both (n = 6). We analyzed 27 of the 34 patients who could be examined for MRD on day 100 after induction therapy. The overall survival (OS) rate (45.0%) and relapse-free survival (RFS) rate (40.0%) at 2 years in CR patients with MRD level ≥ 10^[-3] (n = 12) were significantly lower than those in CR patients with MRD level < 10^[-3] (n = 15) (OS rate: 79.0%, RFS rate: 79.4%) (log-rank test, P = 0.017 and 0.0007). We also applied multicolor flow cytometry for comparison with MRD results analyzed by PCR methods. The comparison of results obtained in 27 follow-up samples showed consistency in 17 samples (63.0%) (P = 0.057). MRD analysis on day 100 is important for treatment decision in adult ALL.
Rights: The final publication is available at
Type: article (author version)
Appears in Collections:医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Submitter: 田中 淳司

Export metadata:

OAI-PMH ( junii2 , jpcoar )

MathJax is now OFF:


Feedback - Hokkaido University